Get the Full Story, Without the Noise.
Published loading...Updated

Novel Alzheimer's therapy shows low risk of severe side effects

Summary by News Medical
The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the field as it represented the first medication of its kind able to influence the disease.

10 Articles

All
Left
Center
3
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Healthing.ca broke the news in Toronto, Canada on Monday, May 12, 2025.
Sources are mostly out of (0)